How to Get Oral Micronized Progesterone in Delaware

What Is Oral Micronized Progesterone and Why Is It Prescribed?

Oral micronized progesterone is a bioidentical form of the hormone progesterone, processed into tiny particles suspended in peanut oil to improve absorption. Physicians prescribe it primarily to protect the uterine lining in women taking estrogen as part of hormone replacement therapy (HRT). Without progesterone opposition, unopposed estrogen raises the risk of endometrial hyperplasia and endometrial cancer.

The PEPI Trial (Postmenopausal Estrogen/Progestin Interventions, N=875) published in JAMA in 1995 established that oral micronized progesterone at 200 mg per day for 12 days per month effectively prevented endometrial hyperplasia while producing a more favorable lipid profile than medroxyprogesterone acetate (MPA). In the PEPI cohort, women receiving conjugated equine estrogen plus cyclic micronized progesterone had zero cases of adenomatous or atypical hyperplasia over three years, compared with a 10% hyperplasia rate in the unopposed estrogen group [1].

The FDA-approved labeling for Prometrium lists two indications: prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women receiving conjugated estrogens, and treatment of secondary amenorrhea [2]. Generic versions carry identical indications. Prometrium capsules contain peanut oil, so women with peanut allergies require a compounded alternative or a different progestogen altogether.

Delaware Telehealth Rules for Progesterone Prescribing

Delaware permits telehealth prescribing for hormone therapy, which means you can consult a licensed provider through a video or audio visit and receive a progesterone prescription without an in-person exam. The state does not require a prior in-person relationship for prescribing non-controlled medications.

The Delaware Board of Medical Licensure and Discipline requires that telehealth prescribers hold an active Delaware medical license or practice under the Interstate Medical Licensure Compact, which Delaware joined in 2017. Nurse practitioners in Delaware have full practice authority under Title 24, Chapter 19, meaning they can independently evaluate, diagnose, and prescribe hormone therapy without physician oversight [3]. Physician assistants may also prescribe under a collaborative agreement with a supervising physician.

A typical telehealth visit for progesterone prescribing takes 20 to 40 minutes. The provider reviews your symptoms, menstrual history (if applicable), surgical history, current medications, and lab results. If labs have not been drawn within the past 6 to 12 months, most providers will order them before writing the prescription. Several national telehealth platforms serve Delaware residents and specialize in hormone therapy for perimenopausal and postmenopausal women.

Required Labs Before Starting Progesterone in Delaware

Most prescribers in Delaware require baseline laboratory work before initiating oral micronized progesterone therapy. Lab requirements are clinician-dependent, but the Endocrine Society's 2015 Clinical Practice Guideline on menopausal hormone therapy recommends a thorough risk assessment before starting any HRT regimen [4].

A standard pre-prescribing lab panel includes the following:

• Serum progesterone. Establishes your baseline level and helps determine whether cyclic or continuous dosing is appropriate.
• Estradiol (E2). Confirms menopausal status and guides the estrogen dose that progesterone will be paired with.
• Follicle-stimulating hormone (FSH). Levels above 30 mIU/mL generally confirm menopause. This test is less useful in women already taking estrogen.
• Comprehensive metabolic panel (CMP). Includes liver function tests (AST, ALT), which matter because oral micronized progesterone undergoes hepatic first-pass metabolism.
• Lipid panel. The PEPI Trial showed that micronized progesterone did not negate estrogen's favorable effect on HDL cholesterol, but baseline lipids remain part of standard cardiovascular risk assessment [1].
• Thyroid panel (TSH, free T4). Thyroid dysfunction mimics many perimenopausal symptoms and affects hormone metabolism.

Some providers also request a transvaginal ultrasound to measure endometrial thickness before starting therapy, particularly if the patient reports any postmenopausal bleeding. The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 149 recommends endometrial evaluation for any postmenopausal bleeding before attributing symptoms to hormone deficiency [5].

Quest Diagnostics and Labcorp both operate multiple draw sites across Delaware, including locations in Wilmington, Dover, and Newark. Many telehealth platforms can order labs electronically and send requisitions directly to these facilities.

How to Fill a Progesterone Prescription in Delaware

Once your prescriber writes the prescription, you have two main options for filling it in Delaware: retail pharmacies carrying FDA-approved Prometrium or its generics, and 503A compounding pharmacies that can prepare custom formulations.

Retail pharmacy (brand and generic). Every major chain pharmacy in Delaware stocks oral micronized progesterone. Generic versions are manufactured by Teva, Mylan, and several other companies. The cash price for a 30-day supply of generic micronized progesterone 200 mg typically ranges from $25 to $60, depending on the pharmacy. Brand-name Prometrium costs substantially more, often $200 to $400 for 30 capsules without insurance. GoodRx and similar discount programs can reduce generic costs to as low as $15 at some Delaware locations.

503A compounding pharmacies. Delaware licenses 503A compounding pharmacies to prepare custom progesterone formulations. This option matters for patients who cannot take Prometrium due to a peanut allergy (the brand capsule uses peanut oil as a suspension medium) or who need non-standard doses. Compounded oral micronized progesterone uses alternative oils such as olive oil. A compounded 30-day supply generally costs $30 to $80. Delaware-licensed 503A pharmacies can ship within the state, and some out-of-state 503A pharmacies with Delaware permits may also ship to Delaware addresses.

The FDA's guidance on 503A compounding outlines requirements: the compound must be based on a valid patient-specific prescription, prepared by a licensed pharmacist, and not be a copy of a commercially available drug unless the prescriber documents a clinical reason for the compounded version (such as the peanut allergy example above) [6].

Delaware Medicaid Coverage and Prior Authorization

Delaware Medicaid covers oral micronized progesterone for endometrial protection in women receiving estrogen therapy, but requires prior authorization (PA). The PA process confirms that the prescription meets the covered indication and is not duplicative with other progestogen therapy.

Prior authorization in Delaware typically requires the following documentation from the prescribing provider:

1. Diagnosis codes. ICD-10 codes for the underlying condition, commonly N95.1 (menopausal and female climacteric states), Z79.890 (long-term use of hormone replacement therapy), or E28.39 (other primary ovarian failure).
2. Lab results. Recent FSH and estradiol levels confirming menopausal status.
3. Estrogen prescription details. The name, dose, and route of the concurrent estrogen product, since progesterone for endometrial protection is indicated only in women with an intact uterus taking estrogen.
4. Clinical rationale. A brief statement explaining why progesterone is medically necessary. For most patients, this is straightforward: the patient has a uterus and is taking systemic estrogen.

PA decisions in Delaware are typically returned within 24 to 72 hours. Emergency or urgent requests can receive a response within 24 hours. If the PA is denied, the prescriber can submit an appeal with additional clinical documentation. The Centers for Medicare & Medicaid Services (CMS) requires state Medicaid programs to provide a formal appeals process for drug coverage denials [7].

For Delaware residents with commercial insurance, most plans cover generic micronized progesterone on their formulary, often at a Tier 1 or Tier 2 copay ($5 to $25). Brand-name Prometrium may sit at a higher tier or require step therapy through a generic first.

Dosing Protocols: Continuous vs. Cyclic

Two dosing schedules dominate clinical practice for endometrial protection. The choice depends on where a patient is in the menopausal transition and her tolerance of withdrawal bleeding.

Continuous combined therapy. The patient takes progesterone 100 mg or 200 mg every night alongside daily estrogen. This approach is standard for postmenopausal women (more than 12 months since the last menstrual period). Continuous dosing reduces the likelihood of scheduled withdrawal bleeding, though some spotting is common during the first three to six months.

Cyclic (sequential) therapy. The patient takes progesterone 200 mg nightly for 12 to 14 days per calendar month, then stops progesterone for the remaining days while continuing estrogen. This schedule produces a predictable withdrawal bleed at the end of each progesterone phase. The PEPI Trial used this cyclic protocol (200 mg for 12 days/month) and demonstrated effective endometrial protection [1]. Cyclic dosing is often preferred for perimenopausal women or those who have recently entered menopause.

The North American Menopause Society (NAMS) 2022 position statement notes that both regimens provide adequate endometrial protection when adherence is maintained, and recommends using the lowest effective dose for the shortest necessary duration consistent with treatment goals [8]. A common off-label use is progesterone 100 mg nightly for sleep support, as the drug's metabolite allopregnanolone has GABAergic sedative properties. This sedating effect is why oral micronized progesterone is typically dosed at bedtime.

Transferring a Progesterone Prescription to Delaware

If you are moving to Delaware or visiting for an extended period and already have an active progesterone prescription from another state, the transfer process is straightforward. Delaware pharmacies accept prescription transfers from out-of-state pharmacies for non-controlled medications. Your current pharmacy can transfer the remaining refills to any Delaware pharmacy electronically or by phone.

Alternatively, a Delaware-licensed telehealth provider can write a new prescription based on your medical records and recent lab work. This may be faster than waiting for a pharmacy transfer, particularly if your current prescription is close to expiring or if your out-of-state provider is not responsive to transfer requests. Bring your most recent lab results and a list of current medications to the telehealth visit. Most providers can issue a new prescription within the same visit.

For patients moving from states with restrictive telehealth rules, Delaware's permissive framework is an advantage. You do not need to establish care with a Delaware provider in person before receiving a telehealth prescription.

Who Can Prescribe Oral Micronized Progesterone in Delaware

Delaware law allows three categories of providers to prescribe oral micronized progesterone.

Physicians (MD/DO). Any physician with an active Delaware medical license can prescribe progesterone. Gynecologists, endocrinologists, and primary care physicians most commonly manage HRT. Delaware participates in the Interstate Medical Licensure Compact (IMLC), which can expedite licensure for physicians practicing via telehealth from other compact states.

Nurse practitioners (NP/APRN). Delaware grants full practice authority to APRNs, meaning nurse practitioners can prescribe, evaluate, and manage hormone therapy independently. No collaborative agreement with a physician is required after completion of a supervised transition period. This is particularly relevant for telehealth access, as NP-led platforms represent a large segment of hormone therapy telehealth services.

Physician assistants (PA). PAs in Delaware prescribe under a collaborative agreement with a supervising physician. The PA's prescriptive authority mirrors the supervising physician's scope, so a PA supervised by a gynecologist or endocrinologist can prescribe HRT including progesterone.

Board-certified menopause practitioners, recognized by NAMS through the Certified Menopause Practitioner (NCMP) credential, may offer more specialized hormonal management, though the NCMP credential is not required for prescribing [9].

Timeline: From Consultation to Receiving Progesterone

Speed matters when symptoms are affecting quality of life. Here is what Delaware residents can realistically expect.

Day 1. Schedule a telehealth appointment. Many platforms offer same-day or next-day availability. If your provider needs labs, they will send a requisition.

Days 2 to 5. Complete lab work at a Delaware draw site. Results typically return within 24 to 48 hours for standard panels.

Days 3 to 7. Follow-up visit (often a brief telehealth check-in) to review results and finalize the prescription. Your provider sends the prescription electronically to your chosen pharmacy.

Days 4 to 10. Pick up the medication or receive it by mail. Retail pharmacies can usually fill a generic progesterone prescription same-day. Compounded prescriptions from 503A pharmacies may take 3 to 7 business days. Mail-order pharmacies ship within 2 to 5 business days.

Total time from initial consultation to medication in hand: roughly 4 to 10 days for most patients. If you already have recent labs (within 6 to 12 months), you can often receive a prescription after a single telehealth visit and pick up the medication the same day.

Safety Considerations and Monitoring

Oral micronized progesterone has a generally favorable safety profile compared to synthetic progestins. The WHI (Women's Health Initiative) observational follow-up and the French E3N cohort study (N=80,377) found that estrogen combined with micronized progesterone did not significantly increase breast cancer risk over a mean follow-up of 8.1 years, in contrast to estrogen plus synthetic progestins [10]. The E3N study reported a relative risk of 1.00 (95% CI 0.83 to 1.22) for estrogen plus micronized progesterone, compared to 1.69 (95% CI 1.50 to 1.91) for estrogen plus synthetic progestins [10].

Prescribers in Delaware typically schedule follow-up visits at 3 months, 6 months, and annually thereafter. Monitoring includes symptom assessment, blood pressure measurement, and periodic lab work (estradiol, progesterone levels, lipid panel, liver function). Any unexpected vaginal bleeding requires evaluation, typically with transvaginal ultrasound and possible endometrial biopsy per ACOG guidelines [5].

Common side effects include drowsiness (reported in 8 to 15% of users), dizziness, and abdominal bloating. The drowsiness is related to allopregnanolone, progesterone's neuroactive metabolite, and is the reason bedtime dosing is standard. Progesterone is contraindicated in patients with active liver disease, known or suspected breast cancer, undiagnosed vaginal bleeding, and known peanut allergy (for Prometrium specifically) [2].

Women with a history of depression should be monitored closely when starting progesterone, as progestogens can exacerbate mood symptoms in some individuals. The Endocrine Society guideline recommends individualized risk-benefit assessment and using the lowest effective dose [4].